Brandon Capital

Respirion Pharmaceuticals is an early-stage biotechnology company focused on developing treatments for respiratory diseases. Originating as a spinout from the Telethon Kids Institute in Perth, the company advances inhaled therapies and antibiotic approaches to combat lung infections, notably in cystic fibrosis. Its product strategy includes an inhaled therapy for cystic fibrosis and an antibiotic program that combines tobramycin with an adjuvant to disrupt bacterial biofilms in the lung, improving antibiotic efficacy. Respirion engages in clinical development partnerships to advance its programs in Australia and the United States, supporting trials through collaborations with life science investors and disease foundations. The company’s approach aims to address the challenges of antibiotic resistance and persistent lung infections by delivering targeted therapies directly to the respiratory tract.

PolyActiva develops therapeutic products for ocular diseases and other applications using a proprietary drug-polymer conjugate technology that enables site-specific drug delivery from medical device components such as implants, films, and fibers. The delivery platform supports administration of small drug products at therapeutic doses over extended periods directly at the target site, via implants, films, or fibers. The company has advanced ocular implants, including latanoprost implants for glaucoma and levofloxacin implants to prevent endophthalmitis after ocular surgery, as well as anti-inflammatory programs. Founded in 2009, PolyActiva is based in Melbourne, Australia, with laboratory facilities in Parkville.

Ena Respiratory Pty Ltd is a biotechnology company based in Melbourne, Australia, focused on transforming the treatment and prevention of respiratory infections. Incorporated in 2020, the company develops synthetic innate immunomodulators aimed at preventing respiratory viral and bacterial infections. Ena Respiratory specializes in novel Toll-like receptor 2 (TLR2) receptor agonists that activate the innate immune system within the respiratory tract. This targeted approach allows for topical delivery to the airways, effectively preventing the dissemination of infections to the lungs. The company's innovations aim to enhance the effectiveness of vaccines and safeguard patients with pre-existing lung conditions from critical complications related to respiratory diseases.

Founded in 2017, Cincera Therapeutics specializes in the discovery and development of small molecule drugs targeting difficult-to-treat inflammatory and fibrotic conditions associated with obesity, metabolic disorders, and cancer.

Denteric is a biotechnology company focused on developing a vaccine to combat periodontal diseases. Based on research from the University of Melbourne and supported by CSL Limited, Denteric's innovative platform targets virulence factors produced by the bacterium Porphyromonas gingivalis, which is associated with various dental diseases. The company's goal is to provide effective treatments that address both the disease itself and its complications, ultimately improving patient health outcomes in the field of dentistry.

Founded in 2017, Cincera Therapeutics specializes in the discovery and development of small molecule drugs targeting difficult-to-treat inflammatory and fibrotic conditions associated with obesity, metabolic disorders, and cancer.

Certa Therapeutics is a clinical-stage biotechnology company developing precision medicines for fibrotic diseases, with a focus on kidney fibrosis. The company uses genetic analysis to identify patients at risk of progressive kidney fibrosis and is developing therapies that block a receptor driving kidney fibrosis, aiming to prevent progression to kidney failure and the need for dialysis or transplantation. Founded in 2017 and based in Melbourne, Australia.